clinical trial · NCT06561386
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Bristol-Myers Squibb·phase3·recruiting·n = 1,000
Non-small Cell Lung CancerNivolumabRelatlimabPembrolizumabCarboplatinPemetrexedCisplatin
brief summary
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%
started
Oct 7, 2024
primary completion
Jul 30, 2030
completion
Aug 4, 2032
last updated
Mar 31, 2026
official title
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol